Abstract:Background CD47,knownasintegrin-associatedreceptorprotein,isover-expressed onnon-small-celllungcancer(NSCLC)cells.Itcaninteractwithsignalregulatory protein-a(SIRPa)andinhibitmacrophagephagocytosis.Autophagy,akeyingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by targeting both CD47 and autophagy. Background ClusterofDifferentiation(CD47),knownasintegrin-associatedreceptor protein,isover-expressedonnon-small-celllungcancer(NSCLC)cells.Itcaninteract withsignalregulatoryprotein-alpha(SIRPa)andinhibitmacrophagephagocytosis. Autophagy, a key ingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by blocking both CD47 and autophagy. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to target CD47onNSCLCcells.Threestandardtechniquesincludingconfocalmicroscope, transmission electron microscope and western blots were used to detect the autophagy in NSCLC cells after CD47 blockade. LDH-release and CFSE staining assay were appliedtodetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy. NSCLC xenograft models were established in BALB/c nude mice to investigate the anti- tumoreffectoftargetingbothCD47andautophagyinNSCLC. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to block CD47onNSCLCcells.Threestandardtechniquesincludingtransmissionelectron microscope, confocal microscope and western blot were used to detect autophagy in NSCLCcellsafterCD47blockade.LDH-releaseandCFSEstainingassaywereapplied todetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy.NSCLC xenograft models were established in BALB/c nude mice to investigate the anti-tumor effectofblockingbothCD47andautophagyinNSCLC. Results WefoundthatblockingCD47couldincreasethephagocytosisandcytotoxicity ofmacrophageagainstNSCLCcells.Duringthisprocess,autophagywastriggered, which was characterized by the three main stages ofautophagic fluxincluding: formation and accumulation ofautophagosomes, fusion ofautophagosomes into lysosomesanddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedcytotoxicity,whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitpotentanti-NSCLCefficacyinvivo. Results WefoundthatblockingCD47couldincreasethephagocytosisofmacrophage against NSCLC cells. During this process, autophagy was triggered, which was characterized by the three main stages ofautophagic fluxincluding: formation andaccumulationofautophagosomes,fusionofautophagosomesintolysosomes anddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedphagocytosis, whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitenhancedanti-NSCLCefficacyinvivo. Conclusions We demonstrated that autophagy was induced in NSCLC cells after CD47 blockade,whileinhibitionofautophagycouldsignificantlyenhancetheanti-tumor efficacyofCD47blockadeinNSCLCs.Ourdataelucidatedthecriticalroleofautophagy inCD47abolishment-basedNSCLStherapyandhighlightedthepotentialapproachfor thetreatmentofNSCLCbyblockingautophagyandCD47. Legal entity responsible for the study N/A Funding the National Natural Science Foundation ofChina (81573332) Disclosure All authors have declared no conflicts ofinterest.

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Cd47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small-Cell Lung Cancer

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

Targeting CD47-SIRPα Axis for Hodgkin and Non-Hodgkin Lymphoma Immunotherapy

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

Targeting CD47-SIRPa axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

Intravenous Delivery of Sirna Targeting Cd47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis

A novel CD47-blocking peptide fused to pro-apoptotic KLA repeat inhibits lung cancer growth in mice

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Anti-CD47 Treatment Enhances Anti-Tumor T-cell Immunity and Improves Immunosuppressive Environment in Head and Neck Squamous Cell Carcinoma

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

399P Blocking CD47 and Autophagy for the Therapy of Non-Small-cell Lung Cancer

Abstract LB-198: Discovery of a Novel Anti-Cd47 Antibody with Anti-Cancer Therapeutic Potential and Minimal RBC Binding

CD47-mediated immune evasion in early-stage lung cancer progression